Otsuka Pharmaceutical Co., Ltd. News Releases /en/release/ Tue, 15 Apr 2025 16:00:00 +0900 Otsuka Pharmaceutical Opens First POCARI SWEAT Factory in VietnamSupporting Health and Meeting Growing Demand /en/company/newsreleases/2025/20250415_1.html Otsuka Pharmaceutical Opens First POCARI SWEAT Factory in VietnamSupporting Health and Meeting Growing Demand Tue, 15 Apr 2025 16:00:00 +0900 Otsuka Pharmaceutical is Focusing on "Water, Nutrition, and Oxygen" to Tap into Human PotentialProvide "Wellness Energy" at Expo 2025 in Osaka, Kansai, Japan /en/company/newsreleases/2025/20250402_1.html Otsuka Pharmaceutical is Focusing on "Water, Nutrition, and Oxygen" to Tap into Human PotentialProvide "Wellness Energy" at Expo 2025 in Osaka, Kansai, Japan Wed, 02 Apr 2025 14:00:00 +0900 Otsuka Files Biologics License Application (BLA) for Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy /en/company/newsreleases/2025/20250331_1.html Otsuka Files Biologics License Application (BLA) for Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy Mon, 31 Mar 2025 08:00:00 +0900 Otsuka Pharmaceutical is Expanding "Local Production and Local Recycling" of PET Bottle Initiatives in Cooperation with Local CommunitiesAgreement Signed with the Saga Eastern Environmental Facilities Association for Horizontal Recycling of PET Bottle /en/company/newsreleases/2025/20250314_1.html Otsuka Pharmaceutical is Expanding "Local Production and Local Recycling" of PET Bottle Initiatives in Cooperation with Local CommunitiesAgreement Signed with the Saga Eastern Environmental Facilities Association for Horizontal Recycling of PET Bottle Fri, 14 Mar 2025 16:00:00 +0900 Rxulti® (brexpiprazole) approved in the European Union for the treatment of schizophrenia in adolescents aged 13 years and older /en/company/newsreleases/2025/20250313_1.html Rxulti® (brexpiprazole) approved in the European Union for the treatment of schizophrenia in adolescents aged 13 years and older Thu, 13 Mar 2025 17:00:00 +0900